Lixte Biotechnology Holdings Inc
$ 3.61
12.11%
17 Apr - close price
- Market Cap 41,940,800 USD
- Current Price $ 3.61
- High / Low $ 3.65 / 3.23
- Stock P/E N/A
- Book Value 0.90
- EPS -1.26
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -1.02 %
- 52 Week High 6.26
- 52 Week Low 0.64
About
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets related to serious common diseases and designs novel compounds to attack those targets. The company is headquartered in East Setauket, New York.
Analyst Target Price
N/A
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-12 | 2025-08-07 | 2025-05-07 | 2025-03-17 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-19 | 2023-11-09 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.3308 | -0.33 | -0.29 | -0.2871 | -0.2746 | -0.4384 | -0.4494 | -0.4318 | -0.4589 | -0.491 | -1.0014 | -0.0821 |
| Estimated EPS | None | None | 0 | None | None | None | None | None | None | None | None | None |
| Surprise | 0 | 0 | -0.29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIXT
2026-04-17 20:10:20
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Guy Warren Primus exchanged equity awards on April 15, 2026. He canceled 25,000 stock options with a $4.05 exercise price and received 25,000 immediately vesting restricted share units, resulting in direct ownership of 25,000 common shares after the transaction. The Form 4 filing details this change in beneficial ownership, explaining the terms of the stock option cancellation agreement and the grant of RSUs.
2026-04-17 20:10:20
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Felix Lourdes canceled 25,000 stock options with a $4.05 exercise price and, in exchange, received 25,000 restricted share units (RSUs). All 25,000 RSUs vested immediately upon grant, and each RSU represents the right to receive one share of common stock. Following these transactions, Lourdes directly holds 25,000 shares of common stock.
2026-04-17 20:10:20
Lixte Biotechnology Holdings (LIXT) has replaced executive and director stock options with immediately vested Restricted Share Units (RSUs) on April 15, 2026. This change affects 350,000 units for the CEO, 50,000 for the CFO, and 25,000 for each of four directors. The company aims to improve leadership retention and align executive incentives more directly with shareholder interests through this new compensation structure.
2026-04-17 20:10:20
Lixte Biotechnology Holdings has cancelled previously granted stock options for its key officers and directors, replacing them with immediately vested Restricted Share Units (RSUs). This strategic move, affecting executives like CEO Geordan Pursglove and CFO Peter Stazzone, aims to enhance retention and incentive mechanisms despite the company trading above its fair value and remaining unprofitable. Additionally, the company recently appointed Sidney Braun as CEO of its subsidiary, Liora Technologies Europe Ltd., demonstrating a focus on strengthening its biotechnology sector position.
2026-04-17 20:10:20
Lixte Biotechnology Holdings, Inc. CFO Peter Stazzone restructured his equity compensation by canceling 50,000 stock options (with a $4.45 exercise price) in exchange for 50,000 restricted stock units (RSUs) on April 15, 2026. These RSUs vested immediately upon grant, giving him direct ownership of 50,000 shares of common stock. This transaction was an internal compensation adjustment, with no open-market buying or selling occurring.
2026-04-17 20:10:20
Michael Andrew Holloway, a director at LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT), restructured his equity compensation by canceling 25,000 stock options and receiving 25,000 restricted share units (RSUs). These RSUs vested immediately upon grant on April 15, 2026, subject to continued service. Following this transaction, Holloway directly holds 25,000 shares of common stock, representing a conversion of his incentive structure rather than a market trade.
